Zacks Research Predicts Increased Earnings for Longeveron

Longeveron Inc. (NASDAQ:LGVN) – Zacks Research increased their Q1 2026 earnings per share estimates for shares of Longeveron in a report issued on Tuesday, March 10th. Zacks Research analyst B. Sorensen now forecasts that the company will post earnings of ($0.23) per share for the quarter, up from their previous forecast of ($1.84). The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. Zacks Research also issued estimates for Longeveron’s Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($1.24) EPS and FY2028 earnings at ($1.19) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Longeveron in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Longeveron presently has a consensus rating of “Hold” and an average price target of $6.50.

Longeveron Stock Down 0.4%

LGVN opened at $0.81 on Thursday. The business has a 50 day moving average price of $0.57 and a two-hundred day moving average price of $0.67. Longeveron has a 52 week low of $0.48 and a 52 week high of $1.92. The company has a market cap of $17.26 million, a PE ratio of -0.76 and a beta of 0.23.

Institutional Trading of Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd acquired a new position in Longeveron Inc. (NASDAQ:LGVN) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 10.01% of the company’s stock.

Longeveron News Roundup

Here are the key news stories impacting Longeveron this week:

• Positive Sentiment: Closed a private placement for up to ~$30M with $15M upfront and a milestone‑driven additional $15M; led by Coastlands Capital with participation from Janus Henderson — proceeds extend runway into 4Q26 and cover the company through the anticipated pivotal Phase 2b ELPIS II topline readout in 3Q26. GlobeNewswire
• Positive Sentiment: Zacks Research sharply raised EPS forecasts across quarters and years (reported March 10), turning several FY/Q estimates materially less negative (e.g., FY2026 revised toward -$0.83 from a far larger loss prior). Analyst upgrades can improve sentiment and lower perceived execution risk as trials progress.
• Neutral Sentiment: Company scheduled to report full‑year 2025 financials and hold a conference call on March 17, 2026 — the release and Q&A are immediate catalysts that could swing the stock depending on guidance and cash‑burn disclosures. Business Insider
• Neutral Sentiment: Recent media coverage (e.g., “A $30 Million Reason to Buy Penny Stock Longeveron”) highlights the financing as a bullish take; such pieces can attract retail attention but are not a substitute for clinical or financial results. Yahoo Finance
• Negative Sentiment: Financing was done at‑the‑market (ATM) under Nasdaq rules — while it provides needed cash, ATM issuances can be dilutive as additional shares may be sold into the market tied to milestones; investors should monitor share count changes and planned use of proceeds. GlobeNewswire

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.